在开始服用联合口服避孕药的妇女中,蛋白S和组织因子通路抑制剂对凝血的影响
Jesper Strandberg1,2, Jette Nybo1, Inger Lise Gade2,3
1The Coagulation Unit, Department of Clinical Biochemistry, Aalborg University Hospital, Aalborg, Denmark.
Research and practice in thrombosis and haemostasis
|September 2, 2025
概括
联合口服避孕药 (COC) 降低了抗凝剂活性,增加了静脉血栓塞栓的风险. 这项研究表明,COCs显著降低了蛋白S和组织因子通路抑制剂的功能,影响了血栓生成.
科学领域:
- 药理学
- 血液学
- 血栓形成研究
背景情况:
- 联合口服避孕药 (COC) 与静脉血栓塞栓症 (VTE) 的风险增加有关.
- COC使用会改变促血凝和抗血凝因素,特别是蛋白S (PS) 和组织因子通路抑制剂 (TFPI).
- 全球血栓生成 (TG) 测定评估整体凝血,使PS和TFPI效应的评估.
研究的目的:
- 研究蛋白S (PS),组织因子通路抑制剂 (TFPI) 和活性蛋白C (APC) 对凝血的影响.
- 在开始使用COC之前和之后,使用TG测定来评估这些影响.
主要方法:
- 研究人员对24名15至34岁的女性进行了研究.
- 血液样本是在基线和启动后3-4个月收集的.
- 使用或不使用抗PS,抗TFPI和APC进行了血栓生成 (TG) 试验,以确定其影响.
主要成果:
- 在COC开始后,正常化的APC敏感度比率增加两倍表明APC敏感度下降.
- 在基线和随访时,抗PS和抗TFPI添加时,TG潜力显著增加.
- 随着抑制剂的阻断,TG潜力的相对增加在随访时变得不那么明显.
结论:
- 使用COC导致抗凝活动在3个月后显著降低.
- 尽管PS活性和TFPI水平略有下降,但整体抗凝功能显著受损.
- 这些发现突出了与COC相关的VTE风险增加的关键机制.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
889
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
889
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Extrinsic and Intrinsic Pathways of Hemostasis
9.2K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
9.2K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
644
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
644
Venous Thrombosis III: Interprofessional Care
22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22
Coagulation
7.4K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
7.4K


